Effects of Dexmedetomidine on Breast Cancer Cell Function in Vitro

Breast Cancer Clinical Trial

Official title:

Effects of Serum From Patients Received Dexmedetomidine During General Anesthesia on Breast Cancer Cell Function in Vitro

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03108937
• Other study ID #: DEX201703
• Status: Completed
• Phase: N/A
• First received: April 6, 2017
• Last updated: October 8, 2017
• Start date: April 12, 2017
• Est. completion date: September 8, 2017

Study information

• Verified date: March 2017
• Source: RenJi Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dexmedetomidine is widely used as an anaesthetic for general anesthesia during surgery. Previous studies in cells and animals show that dexmedetomidine may promote cancer growth. Using serum from breast cancer surgery patients randomized to receive dexmedetomidine or saline during surgery, we investigated the effects of dexmedetomidine on proliferation, migration and metastasis in MCF-7 breast cancer cells in vitro.

Description:

Women diagnosed with breast cancer undergoing elective surgery under general anesthesia will be randomly allocated to dexmedetomidine group or control group. Patients from both groups will receive midazolam, propofol, fentanyl, remifentanil and CIS atracurium for total intravenous anesthesia. BIS value will be controlled between 40-60 during surgery. Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery. Patients of control group will receive same amount of normal saline. Serum will be collected from patients of both groups at before induction and 1h post-surgery. The MCF-7 breast cancer cell line will be treated with patient serum from both groups. The effects of dexmedetomidine on cellular proliferation, migration and metastasis will be measured.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: September 8, 2017
• Est. primary completion date: July 7, 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• ASA grade I-III Age range of 18 to75 Patients diagnosed primary breast cancer(T2-3, N0-2, M0) Patients will have elective adenomammectomy

Exclusion Criteria:

• with history of breast operation Patients diagnosed carcinoma erysipelatodes Severe liver, renal, brain or lung disease with history of opioid addiction Patients diagnosed metastatic breast cancer

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Dexmedetomidine
Patients in the experimental group will receive Dexmedetomidine during surgery.
• saline
Patients in the control group will receive saline but not Dexmedetomidine during surgery.

Locations

Country	Name	City	State
China	Renji Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
RenJi Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	cell proliferation	MCF-7 cells will be cultured with serum from patients of both groups for 24 hours and cell proliferation will be measured	24 hour post-surgery
Secondary	cell migration	MCF-7 cells will be cultured with serum from patients of both groups for 24 hours and cell migration will be measured	24 hour post-surgery
Secondary	cell metastasis	MCF-7 cells will be cultured with serum from patients of both groups for 24 hours and cell metastasis will be measured	24 hour post-surgery